SCHEMBL225628

SCHEMBL225628

CCCC(C)CS(N)(=O)=O

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CA2 P00918 11/20 0.40
CA1 P00915 8/20 0.40
CA14 Q9ULX7 4/20 0.40
CA7 P43166 3/20 0.40
CA12 O43570 2/20 0.40
TSHR P16473 1/20 0.40
CA9 Q16790 1/20 0.36
TP53 P04637 1/20 0.35
METAP1 P53582 1/20 0.31
GRIA4 P48058 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21124793 1.00 CA2 (0.40) CA2CA1CA14CA7CA12
SCHEMBL27951226 0.86 TP53 (0.42) CA2CA1CA14CA7CA12
SCHEMBL30605502 0.84 TP53 (0.50) CA2CA1CA14CA7CA12
SCHEMBL27035150 0.82 TP53 (0.48) CA2CA1CA14CA7CA12
SCHEMBL11688566 0.81 CA1 (0.43) CA2CA1CA7CA9
SCHEMBL23805180 0.80 TSHR (0.40) CA2CA1CA14CA7CA12
SCHEMBL11350925 0.79 TSHR (0.43) CA2CA1CA14CA7CA12
SCHEMBL21761302 0.79
SCHEMBL25445620 0.79
SCHEMBL223997 0.79

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103911615-B Etching agent composite for copper-containing metal 东友精细化工有限公司 2017-08-22 CN claimed
CN-103911615-A Etching agent composition used for copper-contained metal DONGWOO FINE CHEM CO LTD 2014-07-09 CN claimed
US-20230094952-A1 Method for Culturing Hematopoietic Stem Cells Sumitomo Pharma Co., Ltd. (JP) 2023-03-30 US disclosed
EP-4071239-A1 METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS Sumitomo Pharma Co., Ltd. (JP) 2022-10-12 EP disclosed
CN-114901810-A Method for culturing hematopoietic stem cells 住友制药株式会社 2022-08-12 CN disclosed
CN-113508115-A Pyridopyrimidinone and pteridinone compounds as inhibitors of endoribonuclease inositol requiring enzyme I (IRE I A) for the treatment of cancer diseases 基因泰克公司 2021-10-15 CN disclosed
WO-2021132627-A1 METHOD FOR CULTURING HEMATOPOIETIC STEM CELLS 大日本住友製薬株式会社 2021-07-01 WO disclosed
EP-3191471-B1 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND (DE) 2020-03-11 EP disclosed
CN-103911615-B Etching agent composite for copper-containing metal 东友精细化工有限公司 2017-08-22 CN disclosed
EP-3191471-A1 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2017-07-19 EP disclosed
CN-106459071-A New tricyclic quinone derivative 波士顿生物技术公司 2017-02-22 CN disclosed
WO-2000064912-A1 PHOSPHORIC BENZOYL DERIVATIVES AND THEIR USE AS HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 2000-11-02 WO disclosed
EP-0726254-B1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS (JP) 1998-05-06 EP disclosed
EP-0697407-B1 Pyrimidinedione derivatives and antiarrhythmic compositions containing same MITSUI TOATSU CHEMICALS (JP) 1997-06-25 EP disclosed
US-5627193-A MEDICAL DIAGNOSIS, CARDIOVASCULAR DIAORDERS AND PROTECTION OF ORGANS FOR TRANSPLANTATION MITSUI TOATSU CHEMICALS, INC. (JP) 1997-05-06 US disclosed
EP-0726254-A1 Quinoline-4-carbonylguanidine derivates, process for producing the same and pharmaceutical preparations containing the compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-08-14 EP disclosed
EP-0697407-A1 Pyrimidinedione derivatives and antiarrhythmic compositions containing same MITSUI TOATSU CHEMICALS, Inc. (JP) 1996-02-21 EP disclosed
US-5389626-A 3-aryloxmethyl-cephalosporin derivatives, and their medical use SANKYO COMPANY, LIMITED (JP) 1995-02-14 US disclosed
CN-1042153-A 3-aryloxy methyl-cephalosporins derivatives, their preparation and purposes pharmaceutically SANKYO CO (JP) 1990-05-16 CN disclosed
EP-0363223-A2 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use Sankyo Company Limited (JP) 1990-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094952-A1 Method for Culturing Hematopoietic Stem Cells HCLS1, KIT, MCL1 CA2 1709/4885CA1 864/4885CA14 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.